|
Hemato-oncology
Rituximab plus multiagent chemotherapy for newly diagnosed CD20-positive acute lymphoblastic leukemia: a prospective phase II study
Dong Won Baek, Han-Seung Park, Sang Kyun Sohn, Dae Young Kim, Inho Kim, Jae-Sook Ahn, Young Rok Do, Se Ryeon Lee, Hyeon-Seok Eom, Won-Sik Lee, Sung-Hyun Kim, Ho Sup Lee, Yoo Jin Lee, Joon Ho Moon, Je-Hwan Lee; Adult Acute Lymphoblastic Leukemia Working Party, the Korean Society of Hematology
Korean J Intern Med. 2023;38(5):734-746. Published online June 20, 2023
Background/Aims: We performed a prospective study to determine the efficacy and safety of rituximab including chemotherapy in CD20-positive acute lymphoblastic leukemia (ALL).
Methods: Patients with newly diagnosed ALL, aged ≥ 15 years, were eligible for the study if their leukemic blast cells in ..
|
